0001209191-19-053665.txt : 20191018 0001209191-19-053665.hdr.sgml : 20191018 20191018195628 ACCESSION NUMBER: 0001209191-19-053665 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191016 FILED AS OF DATE: 20191018 DATE AS OF CHANGE: 20191018 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NELSEN ROBERT CENTRAL INDEX KEY: 0001219042 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 191158628 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-10-16 0 0001706431 Vir Biotechnology, Inc. VIR 0001219042 NELSEN ROBERT 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 1 0 Common Stock 2019-10-16 4 C 0 11666665 A 12111109 I See footnote Common Stock 2019-10-16 4 C 0 15555554 A 15555554 I See footnote Common Stock 2019-10-16 4 P 0 1000000 20.00 A 1000000 I See footnote Series A-1 Convertible Preferred Stock 2019-10-16 4 C 0 11111110 D Common Stock 11111110 0 I See Footnote Series A-1 Convertible Preferred Stock 2019-10-16 4 C 0 13333332 D Common Stock 13333332 0 I See Footnote Series B Convertible Preferred Stock 2019-10-16 4 C 0 555555 D Common Stock 555555 0 I See Footnote Series B Convertible Preferred Stock 2019-10-16 4 C 0 2222222 D Common Stock 2222222 0 I See Footnote Each share of the Issuer's Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, which is the sole general partner of ARCH Venture Partners IX Overage, L.P., the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person may be deemed to beneficially own the shares held by ARCH Overage, and the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. These shares are directly held by GPLLC. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. Each of the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Each of ARCH IX and ARCH Overage has a pecuniary interest in the shares held by GPLLC. /s/ Howard Horn, Attorney-in-Fact 2019-10-18